Mannitol for acute stroke

D. Bereczki, M. Liu, G. F. Do Prado, I. Fekete

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Background: Mannitol is an osmotic agent and a free radical scavenger which might decrease oedema and tissue damage in stroke. Objectives: To test whether treatment with mannitol reduces short and long-term case fatality and dependency after acute ischaemic stroke or intracerebral haemorrhage (ICH). Search strategy: We searched the Cochrane Stroke Group Trials Register (searched December 2006), MEDLINE (1966 to January 2007), the Chinese Stroke Trials Register (searched November 2006), the China Biological Medicine Database (searched December 2006) and the Latin-American database LILACS (1982 to December 2006). We also searched the database of Masters and PhD degree theses at Sao Paulo University (searched January 2007), and neurology and neurosurgery conference proceedings in Brazil from 1965 to 2006. In an effort to identify further published, ongoing and unpublished studies we searched reference lists and contacted authors of published trials. Selection criteria: We included randomised controlled trials comparing mannitol with placebo or open control in patients with acute ischaemic stroke or non-traumatic intracerebral haemorrhage. Data collection and analysis: Two review authors independently selected trials, assessed quality, extracted data, and performed the data analysis. Main results: Three small trials, involving 226 participants, were included. One trial included patients with presumed ischaemic stroke without computerised tomography (CT) verification, and the other two trials included patients with CT-verified ICH. Data on the primary outcome measure (death and dependency) were not available in any of the trials. Death and disability could be calculated in the larger ICH trial without differences between the mannitol and control groups. Case fatality was not reported in the trial of ischaemic stroke. Case fatality did not differ between the mannitol and control groups in the ICH trials. Adverse events were either not found or not reported. The change in clinical condition was reported in two trials, and the proportion of those with worsening or not improving condition did not differ significantly between mannitol-treated patients and controls. Based on these three trials neither beneficial nor harmful effects of mannitol could be proved. Although no statistically significant differences were found between the mannitol-treated and control groups, the confidence intervals for the treatment effect estimates were wide and included both clinically significant benefits and clinically significant harms as possibilities. Authors' conclusions: There is currently not enough evidence to support the routine use of mannitol in acute stroke patients. Further trials are needed to confirm or refute whether mannitol is beneficial in acute stroke.

Original languageEnglish
Article numberCD001153
JournalCochrane database of systematic reviews (Online)
Issue number3
DOIs
Publication statusPublished - 2007

Fingerprint

Mannitol
Stroke
Cerebral Hemorrhage
Databases
Control Groups
Tomography
Free Radical Scavengers
Neurosurgery
Neurology
MEDLINE
Patient Selection
Brazil
China
Edema
Randomized Controlled Trials
Placebos
Medicine
Outcome Assessment (Health Care)
Confidence Intervals

Keywords

  • Acute disease
  • Brain edema [drug therapy]
  • Brain ischemia [*drug therapy]
  • Cerebral hemorrhage [*drug therapy]
  • Diuretics, osmotic [adverse effects; *therapeutic use]
  • Mannitol [adverse effects; *therapeutic use]

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Mannitol for acute stroke. / Bereczki, D.; Liu, M.; Do Prado, G. F.; Fekete, I.

In: Cochrane database of systematic reviews (Online), No. 3, CD001153, 2007.

Research output: Contribution to journalArticle

@article{f8c40fb0e68f4d059a2f0cdea12579e8,
title = "Mannitol for acute stroke",
abstract = "Background: Mannitol is an osmotic agent and a free radical scavenger which might decrease oedema and tissue damage in stroke. Objectives: To test whether treatment with mannitol reduces short and long-term case fatality and dependency after acute ischaemic stroke or intracerebral haemorrhage (ICH). Search strategy: We searched the Cochrane Stroke Group Trials Register (searched December 2006), MEDLINE (1966 to January 2007), the Chinese Stroke Trials Register (searched November 2006), the China Biological Medicine Database (searched December 2006) and the Latin-American database LILACS (1982 to December 2006). We also searched the database of Masters and PhD degree theses at Sao Paulo University (searched January 2007), and neurology and neurosurgery conference proceedings in Brazil from 1965 to 2006. In an effort to identify further published, ongoing and unpublished studies we searched reference lists and contacted authors of published trials. Selection criteria: We included randomised controlled trials comparing mannitol with placebo or open control in patients with acute ischaemic stroke or non-traumatic intracerebral haemorrhage. Data collection and analysis: Two review authors independently selected trials, assessed quality, extracted data, and performed the data analysis. Main results: Three small trials, involving 226 participants, were included. One trial included patients with presumed ischaemic stroke without computerised tomography (CT) verification, and the other two trials included patients with CT-verified ICH. Data on the primary outcome measure (death and dependency) were not available in any of the trials. Death and disability could be calculated in the larger ICH trial without differences between the mannitol and control groups. Case fatality was not reported in the trial of ischaemic stroke. Case fatality did not differ between the mannitol and control groups in the ICH trials. Adverse events were either not found or not reported. The change in clinical condition was reported in two trials, and the proportion of those with worsening or not improving condition did not differ significantly between mannitol-treated patients and controls. Based on these three trials neither beneficial nor harmful effects of mannitol could be proved. Although no statistically significant differences were found between the mannitol-treated and control groups, the confidence intervals for the treatment effect estimates were wide and included both clinically significant benefits and clinically significant harms as possibilities. Authors' conclusions: There is currently not enough evidence to support the routine use of mannitol in acute stroke patients. Further trials are needed to confirm or refute whether mannitol is beneficial in acute stroke.",
keywords = "Acute disease, Brain edema [drug therapy], Brain ischemia [*drug therapy], Cerebral hemorrhage [*drug therapy], Diuretics, osmotic [adverse effects; *therapeutic use], Mannitol [adverse effects; *therapeutic use]",
author = "D. Bereczki and M. Liu and {Do Prado}, {G. F.} and I. Fekete",
year = "2007",
doi = "10.1002/14651858.CD001153.pub2",
language = "English",
journal = "Cochrane Database of Systematic Reviews",
issn = "1361-6137",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Mannitol for acute stroke

AU - Bereczki, D.

AU - Liu, M.

AU - Do Prado, G. F.

AU - Fekete, I.

PY - 2007

Y1 - 2007

N2 - Background: Mannitol is an osmotic agent and a free radical scavenger which might decrease oedema and tissue damage in stroke. Objectives: To test whether treatment with mannitol reduces short and long-term case fatality and dependency after acute ischaemic stroke or intracerebral haemorrhage (ICH). Search strategy: We searched the Cochrane Stroke Group Trials Register (searched December 2006), MEDLINE (1966 to January 2007), the Chinese Stroke Trials Register (searched November 2006), the China Biological Medicine Database (searched December 2006) and the Latin-American database LILACS (1982 to December 2006). We also searched the database of Masters and PhD degree theses at Sao Paulo University (searched January 2007), and neurology and neurosurgery conference proceedings in Brazil from 1965 to 2006. In an effort to identify further published, ongoing and unpublished studies we searched reference lists and contacted authors of published trials. Selection criteria: We included randomised controlled trials comparing mannitol with placebo or open control in patients with acute ischaemic stroke or non-traumatic intracerebral haemorrhage. Data collection and analysis: Two review authors independently selected trials, assessed quality, extracted data, and performed the data analysis. Main results: Three small trials, involving 226 participants, were included. One trial included patients with presumed ischaemic stroke without computerised tomography (CT) verification, and the other two trials included patients with CT-verified ICH. Data on the primary outcome measure (death and dependency) were not available in any of the trials. Death and disability could be calculated in the larger ICH trial without differences between the mannitol and control groups. Case fatality was not reported in the trial of ischaemic stroke. Case fatality did not differ between the mannitol and control groups in the ICH trials. Adverse events were either not found or not reported. The change in clinical condition was reported in two trials, and the proportion of those with worsening or not improving condition did not differ significantly between mannitol-treated patients and controls. Based on these three trials neither beneficial nor harmful effects of mannitol could be proved. Although no statistically significant differences were found between the mannitol-treated and control groups, the confidence intervals for the treatment effect estimates were wide and included both clinically significant benefits and clinically significant harms as possibilities. Authors' conclusions: There is currently not enough evidence to support the routine use of mannitol in acute stroke patients. Further trials are needed to confirm or refute whether mannitol is beneficial in acute stroke.

AB - Background: Mannitol is an osmotic agent and a free radical scavenger which might decrease oedema and tissue damage in stroke. Objectives: To test whether treatment with mannitol reduces short and long-term case fatality and dependency after acute ischaemic stroke or intracerebral haemorrhage (ICH). Search strategy: We searched the Cochrane Stroke Group Trials Register (searched December 2006), MEDLINE (1966 to January 2007), the Chinese Stroke Trials Register (searched November 2006), the China Biological Medicine Database (searched December 2006) and the Latin-American database LILACS (1982 to December 2006). We also searched the database of Masters and PhD degree theses at Sao Paulo University (searched January 2007), and neurology and neurosurgery conference proceedings in Brazil from 1965 to 2006. In an effort to identify further published, ongoing and unpublished studies we searched reference lists and contacted authors of published trials. Selection criteria: We included randomised controlled trials comparing mannitol with placebo or open control in patients with acute ischaemic stroke or non-traumatic intracerebral haemorrhage. Data collection and analysis: Two review authors independently selected trials, assessed quality, extracted data, and performed the data analysis. Main results: Three small trials, involving 226 participants, were included. One trial included patients with presumed ischaemic stroke without computerised tomography (CT) verification, and the other two trials included patients with CT-verified ICH. Data on the primary outcome measure (death and dependency) were not available in any of the trials. Death and disability could be calculated in the larger ICH trial without differences between the mannitol and control groups. Case fatality was not reported in the trial of ischaemic stroke. Case fatality did not differ between the mannitol and control groups in the ICH trials. Adverse events were either not found or not reported. The change in clinical condition was reported in two trials, and the proportion of those with worsening or not improving condition did not differ significantly between mannitol-treated patients and controls. Based on these three trials neither beneficial nor harmful effects of mannitol could be proved. Although no statistically significant differences were found between the mannitol-treated and control groups, the confidence intervals for the treatment effect estimates were wide and included both clinically significant benefits and clinically significant harms as possibilities. Authors' conclusions: There is currently not enough evidence to support the routine use of mannitol in acute stroke patients. Further trials are needed to confirm or refute whether mannitol is beneficial in acute stroke.

KW - Acute disease

KW - Brain edema [drug therapy]

KW - Brain ischemia [drug therapy]

KW - Cerebral hemorrhage [drug therapy]

KW - Diuretics, osmotic [adverse effects; therapeutic use]

KW - Mannitol [adverse effects; therapeutic use]

UR - http://www.scopus.com/inward/record.url?scp=38349146259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349146259&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD001153.pub2

DO - 10.1002/14651858.CD001153.pub2

M3 - Article

C2 - 11279707

AN - SCOPUS:38349146259

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

SN - 1361-6137

IS - 3

M1 - CD001153

ER -